ADVICENNE overview

Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, provides an update on recent exchanges with the U.S. FDA (Food and Drug Administration) about the development of ADV7103 in cystinuria, and announces that it has reached an important milestone. As previously stated, the company has engaged in a new round of discussions...

Regulatory News: Advicenne (Euronext Growth Paris ALDVI – FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces that gross sales reached €4.8 million for the 2024 financial year, up 9.2% on the previous year. Gross sales do not include royalties from partners on sales in their respective territories, estimated at €0.5 million for 2024. Sibnayal® mostly drove...

Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announced the conclusion of an agreement with Primex Pharmaceuticals AG, a Swiss biopharmaceutical company. This agreement finalizes the restructuring of contracts signed in 2016. Under this agreement, Advicenne will receive 3.5 million euros, half of which will...

Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2025 financial communication calendar. Event Date* 2024 sales release January 23, 2025 2024 annual financial statement March 27, 2025 AGM May 15, 2025 2025 First Half financial statement September 18, 2024 *: subject to change. End of trading About...